Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2

doi:10.18632/oncotarget.6150

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/18193

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/18193

Title:	Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Authors:	Tung, M.-C.;Lin, P.-L.;Wang, Y.-C.;He, T.-Y.;Lee, M.-C.;Yeh, S.-D.;Chen, Chen C.-Y.;Lee, H.
Keywords:	Cisplatin sensitivity;Lung cancer;Nrf2;P53
Date:	2015
Issue Date:	2017-08-08T09:49:36Z (UTC)
Publisher:	Impact Journals LLC
ISSN:	19492553
Abstract:	Nrf2 is a key transcription factor for genes coding for antioxidants, detoxification enzymes, and multiple drug resistance and it also confers resistance to anticancer drugs. Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Luciferase reporter assays and real-time PCR analysis indicated that the Nrf2 promoter activity and its mRNA levels were markedly suppressed by wild-type p53, but not by mutant p53. Chromatin immunoprecipitation (ChIP) further confirmed that wild-type p53 binds at the p53 putative binding site to block Sp1 binding to the Nrf2 promoter and consequently to suppress the Nrf2 promoter activity. The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC.
URI:	http://dx.doi.org/10.18632/oncotarget.6150 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84951854535&doi=10.18632%2foncotarget.6150&partnerID=40&md5=d6f7665acfef1b660151e8fea44c2246 https://ir.csmu.edu.tw:8080/ir/handle/310902500/18193
Relation:	Oncotarget 6(39) ,41692-41705
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

There are no files associated with this item.

Loading...